Table 1.
Characteristics of the study population at baseline and study start
| PsA group n = 41 | Control group n = 42 | P-value | |
|---|---|---|---|
| Sex | 0.347 | ||
| Women n (%) | 26 (63.4) | 31 (73.8%) | |
| Men n (%) | 15 (36.6) | 11 (26.2%) | |
| Age, years | 54.0 (48.5; 62.0) | 54.5 (46.2;60.0) | 0.450 |
| Body measurements | |||
| Body height, cm | 168.0 (161.5; 176.8) | 165.5 (162.0; 171.5) | 0.171 |
| Body weight, kg | 106.3 (95.8; 113.6) | 107.0 (97.0; 122.2) | 0.313 |
| Pharmacological treatment | |||
| Anti-hypertensives, n (%) | 18 (43.9) | 18 (42.9) | 0.923 |
| Lipid lowering therapy, n (%) | 6 (14.6) | 11 (26.2) | 0.192 |
| Oral anti-diabetics, n (%) | 1 (2.4) | 4 (9.5) | 0.360 |
For categorical variables, number (percentage) is presented. For continuous variables, median (IQR) per participant is presented